Intermittent FastingNCT05558423
ZOE Health Study: The Intermittent Fasting Study
A study testing Time Restricted Eating in people with Intermittent Fasting and Time Restricted Feeding, run by Zoe Global Limited at 1 site in United Kingdom.
Trial summary
The timing of food intake (chrononutrition) is emerging as a key regulator of circadian rhythm in metabolic organs. A wealth of research has been conducted on intermittent fasting, and time restricted eating (TRE) specifically, investigating the temporal patterns of diet (eating window, time of eating, time of largest… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Intermittent Fasting, Time Restricted Feeding
- What is being tested?
- Time Restricted Eating
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 24 Oct 2022to 24 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults of 18 years and above, where the app has been approved for download from the Apple App and Google Play stores.
Who cannot join
- Unable to provide written informed consent
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site, 1 recruiting
- Recruiting
ZOE Limited
London, SE1 7RW
Christina Hu, 07950 335916, zoehealthstudy@kcl.ac.uk
About this study
Official title: The Intermittent Fasting ZOE Health Study: Effects on Hunger, Mood, Energy and Symptom Burden in a UK Cohort
The timing of food intake (chrononutrition) is emerging as a key regulator of circadian rhythm in metabolic organs. A wealth of research has been conducted on intermittent fasting, and time restricted eating (TRE) specifically, investigating the temporal patterns of diet (eating window, time of eating, time of largest energy intake) and their impact on disease risk, with overall beneficial impact on health. Studies have been conducted in a parallel or single arm design, while cross-over and the efficacy of TRE in ameliorating appetite and symptom burden within an individual remains unclear.
Read the detailed description
Time Restricted Eating (TRE; a type of intermittent fasting) is a dietary pattern based on the 24h day. Practicing individuals restrict their eating/feeding window to a certain number of hours, e.g. 4h, while the remaining hours in the day are non-feeding (fasting) time. The eating window is the duration of time from the start of the first meal to the end of the last meal in a 24 hr period. The eating window in a general population has previously been quantified at 12h (American cohort of n=15,000). It is important to note that TRE differs from other intermittent fasting protocols by (i) not specifying a change in dietary intake, such as requiring caloric restriction, but rather specifying the temporal pattern of intake; and (ii) requiring consistent daily eating windows over several days. TRE protocols can vary in the length of the eating window, as well as the anchoring of that window to the time of day, such that early vs. middle vs. late TRE regimens exist.
While the cardiometabolic benefits TRE are well established by human trials, other outcomes of dietary compliance remain unexplored and thus bring into question the sustainability of and adherence to TRE as a long-term dietary regimen. Perception of hunger, mood and energy, and self-elected timings of TRE eating windows while following the dietary pattern are not well understood. In particular, the relative differences in these outcomes between an habitual and a TRE eating pattern within the same individual must be determined in order to truly evaluate the acceptability of TRE on a per-individual basis.
The Intermittent Fasting Study, a sub-study of the ZOE Health Study (ZHS), will test the effects of habitual eating patterns vs. a TRE protocol on hunger, mood, energy and symptom burden in an adult UK cohort using the ZHS app.
Population:
This study is open to all participants currently enrolled in the ZHS study tracking physical and mental symptom burden on a daily basis. Participants will be invited to take part in the Intermittent Fasting Study and must provide their consent in order to participate.
Design:
The study will take place remotely using a n-of-1 design, consisting of two phases with a non-randomised cross-over. Firstly, the participant will complete a baseline phase of one week, where they follow their habitual eating pattern.
Secondly, for the second and third weeks of the study, the participant will be asked to follow a TRE regimen with an eating window of ≤10 hours. The exact duration of the eating window, its timing relative to time of day, and participant dietary intake, are decisions deliberately left to the participant for two reasons; (i) to enable the participant to choose exactly the right TRE protocol that is most acceptable to them and therefore most likely to be sustainable in the long-term; (ii) to understand the trends in acceptability and feasibility of TRE regimens across this UK cohort. The participant is given the option of continuing their TRE phase beyond the minimum two weeks.
During the two phases, participants are asked to log the following outcomes in the ZHS app, on a daily basis:
- Hunger (using visual analogue scales, VAS)
- Mood (using VAS)
- Energy (using VAS)
- Symptom burden (using VAS)
- Body weight (optional)
- Clock time of the start of their first eating event
- Clock time of the end of their last eating event
Participants may also be asked to log their diet during their baseline phase and their TRE phase (optional) such that the temporal effect of changing between their habitual and chosen TRE regimens on dietary intake can be determined. They will also be asked to complete questionnaires, at the start and end of the study, about their eating habits, gastrointestinal health, lifestyle and demographic.
Outcome analysis may be stratified according to demographic and other exposure parameters such as early vs. late TRE.
- Conditions
- Intermittent Fasting, Time Restricted Feeding
- Being tested
- Time Restricted Eating
- Keywords
- Intermittent Fasting, Time Restricted Eating, Hunger, Mood, Energy
- Medical subject headings
- Intermittent Fasting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Time Restricted EatingBehavioural
Participants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours.
| Study group | Role | What they receive |
|---|---|---|
| Self-controlled | Experimental | n-of-1 design. Participants complete a baseline habitual eating phase following by an intervention TRE phase. Receives: Behavioral: Time Restricted Eating |
What is being measured
The primary outcome is the main question the study is designed to answer.
TRE window clock time
The chosen clock time for the TRE window (early, vs. middle, vs. late)
Measured: 2 weeks
Habitual eating window clock time
The chosen clock time for the habitual eating window
Measured: 1 weeks
Hunger
Hunger levels reported by visual analogue scale ("how hungry did you feel yesterday?"; 0-10; where 10 is the most hungry)
Measured: 3 weeks (plus optional unlimited weeks)
Mood
Mood levels reported by visual analogue scale ("how was your mood yesterday?"; 0-10; where 10 is most positive)
Measured: 3 weeks (plus optional unlimited weeks)
Energy
Energy levels reported by visual analogue scale ("how energetic did you feel yesterday?"; 0-10; where 10 is most energetic)
Measured: 3 weeks (plus optional unlimited weeks)
Symptom burden
The self-reported symptom burden while completing both habitual and TRE phases
Measured: 3 weeks (plus optional unlimited weeks)
Secondary outcomes (3)
Body weight
Self-reported in the study app (optional)
Measured: 3 weeks (plus optional unlimited weeks)
Gastrointestinal symptoms
Gastrointestinal symptoms self-reported by questionnaire
Measured: 3 weeks (plus optional unlimited weeks)
Eating habits
Eating habits self-reported by questionnaire, including number of main meals and snacks per day
Measured: 3 weeks (plus optional unlimited weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2022
- Study start24 Oct 2022
- Primary completion24 Oct 2023 (estimated)
- Study completion24 Oct 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intermittent FastingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zoe Global Limited
- Sponsor type
- University, hospital or other
- Collaborators
- King's College London
- Responsible party
- Sponsor
- Investigators
- Tim Spector, Pr, Principal investigator, Zoe Ltd, King's College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05558423
- Sponsor's protocol ID
- ZHS-IF
- Status last verified
- Sep 2022
- First submitted
- 23 Sep 2022
- Last updated
- 30 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Intermittent Fasting ZOE Health Study: Effects on Hunger, Mood, Energy and Symptom Burden in a UK Cohort
- ClinicalTrials.gov ID
- NCT05558423
- Acronym / sponsor ID
- ZHS-IF
- Conditions
- Intermittent Fasting, Time Restricted Feeding
- Keywords
- Intermittent Fasting, Time Restricted Eating, Hunger, Mood, Energy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150,000 participants (estimated)
- Lead sponsor
- Zoe Global LimitedUniversity, hospital or other
- Collaborators
- King's College London
- Study start
- 24 Oct 2022 (actual)
- Primary completion
- 24 Oct 2023 (estimated)
- Study completion
- 24 Oct 2023 (estimated)
- First posted
- 28 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The timing of food intake (chrononutrition) is emerging as a key regulator of circadian rhythm in metabolic organs. A wealth of research has been conducted on intermittent fasting, and time restricted eating (TRE) specifically, investigating the temporal patterns of diet (eating window, time of eating, time of largest energy intake) and their impact on disease risk, with overall beneficial impact on health. Studies have been conducted in a parallel or single arm design, while cross-over and the efficacy of TRE in ameliorating appetite and symptom burden within an individual remains unclear.
Detailed description
Time Restricted Eating (TRE; a type of intermittent fasting) is a dietary pattern based on the 24h day. Practicing individuals restrict their eating/feeding window to a certain number of hours, e.g. 4h, while the remaining hours in the day are non-feeding (fasting) time. The eating window is the duration of time from the start of the first meal to the end of the last meal in a 24 hr period. The eating window in a general population has previously been quantified at 12h (American cohort of n=15,000). It is important to note that TRE differs from other intermittent fasting protocols by (i) not specifying a change in dietary intake, such as requiring caloric restriction, but rather specifying the temporal pattern of intake; and (ii) requiring consistent daily eating windows over several days. TRE protocols can vary in the length of the eating window, as well as the anchoring of that window to the time of day, such that early vs. middle vs. late TRE regimens exist.
While the cardiometabolic benefits TRE are well established by human trials, other outcomes of dietary compliance remain unexplored and thus bring into question the sustainability of and adherence to TRE as a long-term dietary regimen. Perception of hunger, mood and energy, and self-elected timings of TRE eating windows while following the dietary pattern are not well understood. In particular, the relative differences in these outcomes between an habitual and a TRE eating pattern within the same individual must be determined in order to truly evaluate the acceptability of TRE on a per-individual basis.
The Intermittent Fasting Study, a sub-study of the ZOE Health Study (ZHS), will test the effects of habitual eating patterns vs. a TRE protocol on hunger, mood, energy and symptom burden in an adult UK cohort using the ZHS app.
Population:
This study is open to all participants currently enrolled in the ZHS study tracking physical and mental symptom burden on a daily basis. Participants will be invited to take part in the Intermittent Fasting Study and must provide their consent in order to participate.
Design:
The study will take place remotely using a n-of-1 design, consisting of two phases with a non-randomised cross-over. Firstly, the participant will complete a baseline phase of one week, where they follow their habitual eating pattern.
Secondly, for the second and third weeks of the study, the participant will be asked to follow a TRE regimen with an eating window of ≤10 hours. The exact duration of the eating window, its timing relative to time of day, and participant dietary intake, are decisions deliberately left to the participant for two reasons; (i) to enable the participant to choose exactly the right TRE protocol that is most acceptable to them and therefore most likely to be sustainable in the long-term; (ii) to understand the trends in acceptability and feasibility of TRE regimens across this UK cohort. The participant is given the option of continuing their TRE phase beyond the minimum two weeks.
During the two phases, participants are asked to log the following outcomes in the ZHS app, on a daily basis:
- Hunger (using visual analogue scales, VAS)
- Mood (using VAS)
- Energy (using VAS)
- Symptom burden (using VAS)
- Body weight (optional)
- Clock time of the start of their first eating event
- Clock time of the end of their last eating event
Participants may also be asked to log their diet during their baseline phase and their TRE phase (optional) such that the temporal effect of changing between their habitual and chosen TRE regimens on dietary intake can be determined. They will also be asked to complete questionnaires, at the start and end of the study, about their eating habits, gastrointestinal health, lifestyle and demographic.
Outcome analysis may be stratified according to demographic and other exposure parameters such as early vs. late TRE.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Self-controlled | Experimental | Behavioral: Time Restricted Eatingn-of-1 design. Participants complete a baseline habitual eating phase following by an intervention TRE phase. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Adults of 18 years and above, where the app has been approved for download from the Apple App and Google Play stores.
Key exclusion criteria (1 listed)
- Unable to provide written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Time Restricted EatingParticipants are asked to follow a Time Restricted Eating regimen with eating window of ≤10 hours. | Behavioural | Self-controlled |
Primary outcome
TRE window clock time
Time frame: 2 weeks
The chosen clock time for the TRE window (early, vs. middle, vs. late)
Habitual eating window clock time
Time frame: 1 weeks
The chosen clock time for the habitual eating window
Hunger
Time frame: 3 weeks (plus optional unlimited weeks)
Hunger levels reported by visual analogue scale ("how hungry did you feel yesterday?"; 0-10; where 10 is the most hungry)
Mood
Time frame: 3 weeks (plus optional unlimited weeks)
Mood levels reported by visual analogue scale ("how was your mood yesterday?"; 0-10; where 10 is most positive)
Energy
Time frame: 3 weeks (plus optional unlimited weeks)
Energy levels reported by visual analogue scale ("how energetic did you feel yesterday?"; 0-10; where 10 is most energetic)
Symptom burden
Time frame: 3 weeks (plus optional unlimited weeks)
The self-reported symptom burden while completing both habitual and TRE phases
3 secondary outcomes
Body weight
Time frame: 3 weeks (plus optional unlimited weeks)
Gastrointestinal symptoms
Time frame: 3 weeks (plus optional unlimited weeks)
Eating habits
Time frame: 3 weeks (plus optional unlimited weeks)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2022.
- Individual participant dataSharing planned: No
Related trials for Intermittent Fasting
Recruiting
Intermittent Fasting Versus Carbohydrate Drinks Before Surgery
Perioperative Care, Intermittent Fasting
Active, not recruiting
Nested Pilot Study Comparing Two Treatments to Reduce Type 2 Diabetes Risk in At-Risk Delawareans
Prediabetes
Not yet recruiting
Time-Restricted Eating and Personalized Energy-Restricted Diet in Obese Postmenopausal Women
Obesity (BMI Equal to or >30), Postmenopausal Symptoms
Not yet recruiting
Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial
Polycystic Ovary Syndrome
Not yet recruiting
Time-restricted Eating and High-intensity Interval Training After Gestational Diabetes
Gestational Diabetes Mellitus With Baby Delivered
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tim Spector, Pr principal investigator
Zoe Ltd, King's College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Time Restricted Eating in people with Intermittent Fasting and Time Restricted Feeding, run by Zoe Global Limited at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christina Hu (07950 335916, zoehealthstudy@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
TRE window clock time (time frame: 2 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2022.